Rick Finnegan

Rick Finnegan has worked in the pharmaceutical industry since 1989. Their career began at Merck, where they held several roles, including Global Franchise Lead - Anti-infectives, Sr. Director Marketing Planning (FOSAMAX), Director - Managed Care Marketing and Disease Management, Sr. Product Manager (PROSCAR), and Product Manager (VASOTEC). Rick also participated in the International Marketing Management Training Program. In 2001, they moved to Genzyme, where they were a VP New Product Marketing. Rick then joined Critical Therapeutics in 2003 as SVP Sales & Marketing. In 2007, Rick moved to GTC Biotherapeutics as VP Corporate Development, followed by Glenmark Pharmaceuticals in 2008 as President, Specialty Pharma, Europe. In 2010, they joined inVentiv Health as Executive Vice President, Global Strategic Accounts and Commercial Development. In 2014, they moved to rEVO Biologics as Senior Vice President Operations and Program Management. Finally, in 2018, they joined SAB Biotherapeutics as Chief Business Officer / EVP Program Management, and in 2022 they will become Chief Operating Officer at Elixirgen Therapeutics, Inc.

Rick Finnegan holds a Master of Science in Management from the MIT Sloan School of Management and a Bachelor of Science in Business Administration and Life Sciences from the UNH Peter T. Paul College of Business and Economics.